Stay updated on Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.

Latest updates to the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page
- Check4 days agoChange DetectedThe page's related topics section no longer includes Lung cancer and MedlinePlus Genetics. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check12 days agoChange DetectedRevision in the page footer updated from v3.2.0 to v3.3.2. This is a system update and does not alter the study information or eligibility criteria.SummaryDifference0.0%

- Check19 days agoChange DetectedAdded topic tags 'Lung cancer' and related 'MedlinePlus Genetics' topics to the page. Removed the government funding status notice about NIH operations.SummaryDifference0.5%

- Check26 days agoChange DetectedThe related topics section now omits Lung cancer and MedlinePlus Genetics, reducing navigational context but not changing the study’s core details; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check33 days agoChange DetectedResults data has been posted for the study (Results First Posted 2025-03-24). Enrollment and primary completion dates have been updated to reflect the latest status.SummaryDifference0.4%

- Check40 days agoChange DetectedLung cancer is added to related topics with a MedlinePlus Genetics link for educational resources.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.